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pression (p < 0.0001). However, the molecular marker 
expression profiles were inhomogeneous and did not 
allow valuable diagnostic outcome prediction. Conclu-
sions: SUV level-based 18F-FDG-PET/CT lymph node as-
sessment in OSCC still has to be considered as the most 
established and reliable staging tool. Lymph node mo-
lecular marker expression profiles need to be investi-
gated further as they currently do not sufficiently con-
tribute to therapy decision-making.
Introduction
Head-and-neck squamous cell cancer (HNSCC), irrespective of 
the primary tumor site, remains a diagnostic and therapeutic chal-
lenge even today. Despite multimodal treatment facilities compris-
ing surgery and laser resection, chemotherapy and radiation, the 
5-year overall survival in these patients is far lower than 50%, espe-
cially in advanced tumor stages with lymph node metastases [1]. 
The patient prognosis is influenced by the quality of pretherapeutic 
staging, which includes assessment of tumor spread, the extent of 
vascular infiltration, and the cervical nodal status [2, 3]. In the era 
of targeted cancer therapy, tumor detection at an early stage and 
follow-up care in due time are integral parts of the treatment pro-
tocol [4–6].
Although 18F-fluorodeoxyglucose (FDG)-positron emission to-
mography (PET)/computed tomography (CT) has not been imple-
mented in the routine diagnostic workup of patients presenting 
with HNSCC, its benefit for initial node (N) staging and assess-
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Summary
Background: A prospective study was performed to as-
sess standard uptake value (SUV)-level based 18F-fluoro-
deoxyglucose (FDG)-positron emission tomography 
(PET)/computed tomography (CT) lymph node staging in 
33 patients with oropharyngeal squamous cell cancer 
(OSCC) out of a total of 99 patients with head-and-neck 
squamous cell cancer (HNSCC) and the role of nodal mo-
lecular marker expression in diagnostic outcome predic-
tion. Methods: Preoperative nodal PET/CT staging in 123 
lymph nodes was correlated with postoperative lymph 
node histology, which served as gold standard. Tissue 
samples were prepared for immunohistochemistry of 
the excised lymph nodes. Results: The negative and pos-
itive predictive values (NPV and PPV) of PET for correct 
lymph node assessment were 100% and 93%, respec-
tively. There was a significant association between SUV-
max and lymph node histology (p < 0.0001) and a signifi-
cant linear correlation between SUVmax and nodal size 
(Pearson’s correlation coefficient r = 0.61336, p < 0.0001). 
The molecular marker E-Cadherin was significantly over-
expressed in lymph node metastases (p < 0.0001). Be-
nign lymph nodes showed significant 2-fold Bcl2 overex-
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ment of lymph node metastases recurrence has been reported in 
several studies [1, 7]. With sensitivities ranging from 87 to 95% and 
specificities of 80–98%, FDG-PET/CT has advanced to an estab-
lished pre- and posttherapeutic imaging tool for cervical lymph 
node involvement in many centers [3, 8]. Limited information is 
available on the prognostic influence of maximum standard uptake 
values (SUVmax) of lymph node metastases on posttherapeutic re-
sponse evaluation and the estimation of recurrence-free survival [1, 
2, 9]. Variations in SUVmax levels and molecular marker expres-
sion patterns in lymph nodes may provide more accurate differen-
tiation between benign and malignant lymph nodes. SUV levels 
and marker composition may also serve as parameter for outcome 
prediction [10, 11].
The aim of this prospective study was to combine initial 18F-
FDG-PET/CT lymph node staging in oropharyngeal squamous cell 
cancer (OSCC) with the assessment of PET-SUV levels and molec-
ular marker expression of the analyzed lymph nodes, with regard 
to their contribution to diagnostic outcome prediction in these 
patients.
Patients and Methods
Patients
From September 2009 until October 2011, a total of 99 patients with initial 
diagnosis of HNSCC underwent nodal staging with 18F-FDG-PET/CT at our 
institution. Prior to PET/CT, in all patients, a clinical examination and ultra-
sound of the neck was performed by an experienced head-and-neck surgeon. In 
64 out of 99 patients with HNSCC, a postoperative correlation between the 
PET/CT findings and lymph node histology was available. 35 patients had to be 
excluded due to unavailable histology (no lymph node resection performed). 31 
patients with non-OSCC tumor location site were excluded from the study. A 
total of 33 patients with exclusively OSCC were included for complete analysis: 
21 male (64%) and 12 female patients (36%), mean age group 58.5 ± 7.8 years 
(range 40–73 years). For these 33 patients, 123 lymph node histologies were 
available. Out of these 123 findings, 63/123 lymph nodes were detected and 
evaluated by PET, whereas the remaining 60/123 lymph nodes were not visible 
in the PET scans due to lack of FDG uptake. The criteria for patient selection in 
this study are illustrated in figure 1. This prospective study was approved by our 
hospital institutional ethics review committee. All enrolled patients gave their 
written informed consent for staging PET/CT before undergoing neck dissec-
tion. The patient informed consent was waived by our institutional ethics 
board.
The treatment regimen for each patient was based on the decision of our 
institutional multidisciplinary tumor board conference. For all patients, a resec-
tion of the primary tumor with bilateral selective neck dissection and adjuvant 
radiochemotherapy (RCT) was planned.
According to the tumor board decision, all 33 patients underwent resection 
of their primary tumors. This was followed by a selective bilateral neck dissec-
tion of the levels 2, 3, and 4. Each neck level was resected individually. For every 
patient, the surgeon obtained a protocol sheet with a neck diagram before sur-
gery. Within this neck diagram, the lymph node findings of PET/CT were plot-
ted. This level-specific lymph node mapping enabled the surgeon to precisely 
mark the lymph nodes of every individual neck level for the pathologist.
After surgery, 28 patients underwent adjuvant RCT. 5 patients refused an 
additional adjuvant treatment. 1 patient who had not undergone adjuvant RCT 
developed a recurrence after 3 months and underwent repeated surgery. The 
other patients who developed a recurrence between 6 and 18 months of their 
follow-up period underwent chemotherapy with cisplatin and 5-fluorouracil (5-
FU). Table 1 gives an overview of the clinical data of all 33 patients with OSCC.
18F-FDG-PET/CT Imaging Protocol
Imaging was performed on a high-definition (HD) PET/CT scanner (Bio-
graph mCT; Siemens Healthcare, Erlangen, Germany) according to a dedicated 
head-and-neck protocol, established in our diagnostic center. Patients received 
a weight-adapted intravenous (i.v.) injection of 250–300 MBq 18F-FDG (ZAG 
Zyklotron AG, Karlsruhe, Germany) after a minimum fasting period of 6 h and 
at a blood glucose level of less than 140 mg/dl. After 60 min of resting, an atten-
uation-corrected low-dose extended-field-of-view (FOV) 780-mm CT was per-
formed from the skull base to the pelvis, with 5 mm slice thickness and 3 mm 
increment (attenuation-corrected computed tomography (AC-CT) 50–70 mAs, 
120 kV; B19f low dose for an ECT 5.0 sensor/3.0 mm increment, scan 5.0 mm, 
slice collimation 16 × 1.2 mm, 0.5 s/rotation, extended FOV > 80 mm). Scan-
ning was performed with the patient in supine position, with arms down. The 
scan time was 3 min per bed position, and all emission images were acquired in 
3-dimensional (3D) mode. Postprocessing of the PET images was obtained with 
a resolution-recovery 3D ordered subset expectation maximization (OSEM) al-
gorithm (3 iterative steps, 24 subsets) on a 200 × 200 matrix. Subsequent to 
PET, every patient received a diagnostic contrast-enhanced biphasic CT from 
the skull base to the base of the lung (tube current 50–120 mAs, tube voltage 
120 kV, slice collimation 16 × 1.2 mm, pitch 0.8, rotation time 0.5 s). The PET/
CT lymph node findings and their SUVmax levels were allocated to cervical re-
gions in the right and left neck and documented in an evaluation sheet, topo-
graphically defined according to the neck dissection nomenclature [12].
PET Analysis and Immunohistochemistry of Cervical Lymph Nodes
Measurement of the SUVmax levels of the cervical lymph nodes was per-
formed with a scanner-integrated software on a dedicated workstation (Siemens 
Syngo TrueD). Individual regions of interest were drawn around the lymph 
nodes and the calculations were documented in an evaluation sheet. The de-
pendence of the semi-quantitative parameter SUVmax on the scanner, the in-
jected FDG dose, the patient weight and the reconstruction methods, and the 
difficulty in defining a cut-off level for benign and malignant lesions are docu-
mented in the literature [7, 11]. On the basis of our previous experience with 
PET/CT head-and-neck imaging and the manufacturer’s hardware and soft-
ware specifications, SUVmax levels < 3 were classified as benign lymph nodes 
whereas SUVmax levels ˰ 3 were characterized as lymph node metastases. 
Lymph node assessment was primarily based on PET-SUV levels in considera-
tion of the corresponding CT slices. Suspicious lymph nodes in PET, histologi-
cally confirmed as malignant, were classified as true-positive findings. Unsuspi-
cious lymph nodes in PET and corresponding SUV levels, histologically con-
firmed as benign, were classified as true-negative findings. Suspicious lymph 
nodes in PET, histologically non-malignant, were classified as false-positive 
Fig. 1. Criteria for patient selection in this study.
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findings. Unsuspicious lymph nodes in PET, histologically confirmed as malig-
nant, were classified as false-negative findings. All characterized lesions under-
went intraoperative exploration and resection with histological correlation.
Tissue samples of 5–7 μm slice thickness (Leica CM 1900) were prepared for 
immunohistochemical analysis with antibodies against vascular endothelial 
growth factor (VEGF), E-Cadherin, epidermal growth factor receptor (EGFR), 
Ki-67, Cyclin D1, Bcl2, human papilloma virus type 16 (HPV-16) and HPV-18 
in the lymph nodes. Individual antibodies and corresponding antigen retrieval 
mechanisms were applied for analysis (table  2). Immunostaining rates were 
classified into 4 scores (1 = no staining, 2 = 1–25% weak staining, 3 = 26–50% 
moderate staining, 4 = 51–100% intense staining).
Statistical Analysis
Assessment was done with SAS software release 9.3 (SAS Institute Inc., 
Cary, NC, USA). For each diagnostic parameter (i.e. PET and histological find-
ings), sensitivity, specificity, and predictive values were analyzed together with 
the corresponding 95% confidence intervals. In order to compare 2 different 
diagnostic methods for lymph node characterization, sensitivities and specifici-
ties were compared with McNemar tests. Furthermore, the kappa index was 
calculated as a measure of agreement. For comparison of the 2 histology groups 
regarding SUVmax and lymph node size, Mann-Whitney tests were applied. 
The trend test according to Cochran and Armitage was used to compare the 2 
histological groups regarding their tumor marker expression levels, which were 
classified into 4 scores. A potential linear relationship between lymph node SU-
Vmax and size was analyzed with Pearson’s correlation coefficient. Further-
more, logistic regression analysis and receiver operating characteristic (ROC) 
analysis were performed in order to determine an optimal SUVmax cut-off 
level for accurate prediction of benign and malignant lymph nodes.
Tumor-specific survival was calculated by Kaplan-Meier analysis. Differ-
ences and correlations were considered as statistically significant for test results 
with p values of < 0.05.
No. Patient  
code
Sex Agea, years TNMb Tumor site ND level RCTx Recurr,  
months
 1 O1 m 73 T3N1M0 Ton 2, 3, 4 no none
 2 O2 f 40 T1N1M0 Ton 2, 3, 4 no 3
 3 O3 m 71 T3N2aM0 Ton, BT,  
SP2, 3, 4
yes none
 4 O4 f 53 T2N1M0 Ton, SP 2, 3, 4 yes none
 5 O5 m 49 T3N0M0 BT 2, 3, 4 yes 18
 6 O7 f 57 T2N1M0 Ton 2, 3, 4 yes none
 7 O8 m 67 T3N0M0 BT 2, 3, 4 yes none
 8 O9 m 46 T3N2bM0 BT 2, 3, 4 yes 18
 9 O11 f 61 T2N2cM0 BT 2, 3, 4 yes none
10 O13 m 58 T3N2bM0 BT 2, 3, 4 yes 18
11 O14 m 58 T3N0M0 Ton, BT, LPW 2, 3, 4 yes none
12 O15 m 65 T3N2bM0 Ton, BT 2, 3, 4 yes 9
13 O18 f 53 T2N2bM0 Ton 2, 3, 4 yes none
14 O20 m 65 T3N0M0 BT 2, 3, 4 yes none
15 O21 m 54 T2N2bM0 Ton 2, 3, 4 yes none
16 O23 f 52 T3N2bM0 Ton 2, 3, 4 yes none
17 O25 f 54 T4N0M0 SP, LPW 2, 3, 4 yes none
18 O26 m 61 T4N2cM0 BT 2, 3, 4 yes 9
19 O28 m 56 T3N2bM0 Ton 2, 3, 4 yes none
20 O29 m 64 T2N2bM0 Ton 2, 3, 4 yes none
21 O30 f 51 T2N2bM0 Ton 2, 3, 4 yes none
22 O32 m 60 T4N2bM0 BT 2, 3, 4 yes none
23 O34 m 52 T3N0M0 Ton, SP 2, 3, 4 no none
24 O35 m 66 T3N1M0 Ton 2, 3, 4 no none
25 O36 f 59 T2N0M0 Ton 2, 3, 4 yes none
26 O38 f 60 T3N2cM0 SP 2, 3, 4 yes 6
27 O39 m 53 T2N3M0 To 2, 3, 4 yes 6
28 O40 m 53 T3N2bM0 SP 2, 3, 4 yes none
29 O41 f 66 T4N2bM0 BT 2, 3, 4 yes none
30 O43 m 70 T3N2cM0 SP, U 2, 3, 4 yes none
31 O44 m 59 T2N1M0 Ton 2, 3, 4 no none
32 O45 m 72 T3N2cM0 BT 2, 3, 4 yes none
33 O48 m 59 T2N2cM0 Ton 2, 3, 4 yes none
aAge at the time of study enrolment.
bTNM classification (Union for International Cancer Control (UICC) 2002).
ND = Neck dissection, RCTx = adjuvant radiochemotherapy, Recurr = recurrence given in months after surgery, m = male, f = female, 
Ton = tonsil, BT = base of tongue, SP = soft palate, U = uvula, LPW = lateral pharyngeal wall.
Table 1. Overview of 
the clinical data of all 
33 patients with OSCC
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Results
Patient Characteristics
A total of 33 patients with exclusively OSCC were included for 
complete analysis (see ‘Patients and Methods’ and fig. 1). In most 
cases, advanced-stage OSCC with stage II n = 1 (3%), stage III n = 
11 (33%), and stage IV n = 21 (64%) was diagnosed. Altogether, 
123 lymph node histologies were available. Out of these 123 find-
ings, 63 lymph nodes were detected and evaluated in PET, based 
on dedicated reading by 2 experienced radiologists and a preopera-
tive mapping by 1 head-and-neck surgeon. 60 additionally excised 
lymph nodes in the surgical specimens were histologically benign. 
They had not been detected in preoperative PET due to lack of 
FDG uptake, which emphasizes the high negative predictive value 
(NPV) of PET/CT [13].
Results of Lymph Node Analysis
Of the 63 PET-visible lymph nodes, 23 (36.5%) were histologi-
cally benign, with 20 true-negative findings and 3 false-positive 
findings (specificity 87%, NPV 100%). 40/63 PET-diagnosed 
lymph nodes (63.5%) proved to be metastases and were correctly 
diagnosed as such (sensitivity 100%, positive predictive value 
(PPV) 93%). Comparing PET diagnosis with histological findings, 
a kappa value of 0.8944 and p = 0.0833 (McNemar test) were ob-
tained. A SUVmax cut-off level of 3.0 was determined for the pre-
diction of benign and malignant lymph nodes. SUVmax of the his-
tologically benign lymph nodes was 3.4 ± 4.1 (1.4–22.0) and their 
average size was 8.9 ± 2.4 mm (5.0–14.0 mm). SUVmax of the ma-
lignant lymph nodes was 9.4 ± 7.1 (3.0–39.1), with an average size 
of 14.7 ± 9.2 mm (7.0–54.0 mm). The Mann-Whitney U test 
proved significantly lower SUVmax levels in benign compared to 
malignant lymph nodes (p < 0.0001) (fig. 2a). Benign lymph nodes 
were significantly smaller in size than nodal metastases (p = 
0.0006) (fig. 2b). A linear relationship could be observed between 
SUVmax and lymph node size (Pearson’s correlation coefficient r 
= 0.61336, p < 0.0001).
Data on Immunohistochemistry
The tumor marker expression levels for VEGF, E-Cadherin, 
EGFR, Ki-67, Cyclin D1, Bcl2, HPV-16, and HPV-18 were very 
heterogeneous (fig. 3a–c). The p values of the Cochran-Armitage 
trend test for staining intensity and lymph node dignity were 
VEGF p = 0.9168, E-Cadherin p < 0.0001, EGFR p = 0.6029, Ki-67 
p = 0.8205, Cyclin D1 p = 0.4612, Bcl2 p = 0.0001, HPV-16 p = 
0.8227, and HPV-18 p = 0.1279. Hence, as a potential diagnostic 
tool for distinguishing between benign and malignant lymph 
nodes, only the expression levels of E-Cadherin and Bcl2 showed 
statistical significance justifying further consideration. Because of 
the statistically non-significant results for HPV-16 and -18, these 
markers were not considered for further diagnostic assessment.
In the lymph node metastases, E-Cadherin expression was sig-
nificantly increased (with median values of 3 and 1, respectively) as 
Antibody against Type Dilution Antigen retrieval Company
VEGF polyclonal rabbit 1:200 citrate buffer Santa Cruz, Heidelberg, Germany
E-Cadherin monoclonal mouse 1:50 citrate buffer Abcam, Cambridge, UK
EGFR monoclonal mouse 1:100 citrate buffer Santa Cruz, Heidelberg, Germany
Ki-67 monoclonal mouse 1:100 citrate buffer DAKO, Hamburg, Germany
Cyclin D1 monoclonal mouse 1:100 citrate buffer Abcam, Cambridge, UK
Bcl2 monoclonal mouse 1:50 citrate buffer Acris, Herford, Germany
HPV-16 monoclonal mouse 1:100 citrate buffer Abcam, Cambridge, UK
HPV-18 monoclonal mouse 1:20 citrate buffer Abcam, Cambridge, UK
Table 2. Antibodies 
for immunohistochem-
ical analysis

Fig. 2. Relation between SUVmax and lymph node histology (a) and nodal 
size and histology (b). Benign lymph nodes present with less average SUVmax 
levels and size than lymph node metastases.
Fig. 3. Intensity of staining and immunomarker 
expression for E-Cadherin (a), Cyclin D (b), and 
Bcl2 (c) in lymphatic tissue. Scores: 1 = no staining, 
2 = 1–25% weak staining, 3 = 26–50% moderate 
staining, 4 = 51–100% intense staining.
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well as the SUVmax levels (median values 6.8 and 2.6, p < 0.0001 
with Mann-Whitney U test). Benign lymph nodes with corre-
sponding lower SUVmax levels showed significant overexpression 
of Bcl2 (median values 4 and 2, respectively) (fig. 4a–c).
Patient Survival Outcome
Out of the 33 patients with OSCC, 24 patients (73%) survived 
and 9 patients (27%) died during a mean follow-up period of 23.6 
months (3–35 months, median 25 months). 5 out of 9 patients died 
of tumor recurrence after 10 (2 ×), 11, 12, and 27 months. In these 
5 patients, advanced disease was diagnosed according to tumor/
node/metastasis (TNM) criteria (T3: 4 ×, T4: 1 ×; N2b: 3 ×, N2c: 2 
×). In 4 cases, non-cancer-related death occurred after 3, 7, 17, and 
30 months. These 4 patients presented with T3 stage OSCC with 
no nodal involvement in 3 cases and N2a stage in 1 patient. Data 
for tumor-specific survival time up to 35 months was available for 
28 patients, including 4 patients with non-cancer-related death 
(fig. 5).
Discussion
Despite dedicated examination protocols for the diagnosis of 
HNSCC, these tumors represent a multifactorial disease with mo-
lecular and immunohistochemical heterogeneity. Precision medi-
cine delivering targeted antiangiogenic tumor treatment seems to 
be a new approach to this tumor entity [10, 13, 14].
In this study, the key role of 18F-FDG-PET/CT for lymph node 
staging in OSCC could be confirmed and also the value of the PET-
SUV level as a prognostic marker, although in the clinical setting 
18F-FDG-PET/CT is still not considered a standard in HNSCC 
staging. An experienced head-and-neck surgeon will not base the 
therapy decision entirely on imaging findings, especially in patients 
with clinically negative neck. Kyzas et al. [15] performed a meta-
analysis of 32 studies in HNSCC patients, demonstrating consider-
ably decreased sensitivity and specificity of 18F-FDG-PET alone in 
non-palpable occult cervical metastasis.
Nevertheless, there is increasing evidence suggesting the inte-
gration of combined 18F-FDG-PET/CT for nodal staging, cancer 
of unknown primary (CUP) detection, and recurrence surveillance 
[16]. PET/CT scanner technology, dedicated imaging protocols, 
and high-quality postprocessing software are improving the diag-
nostic output in lymph node staging [6, 17]. Still, the ‘N0 neck’ 
continues to be a challenge despite increased diagnostic accuracy 
of up to 95%, by combining high-resolution PET with contrast-
enhanced CT [18].
Assessment of the SUVmax has been feasible in many tumor 
entities, and its value is in agreement with several studies [11, 17, 
19]. Some authors assume that the SUVmax is not a valuable pa-
rameter for outcome prediction [17, 20]. We are not of this opin-
ion and agree with Kubicek et al. [1] that the SUVmax correlates 
with lymph node histology and size, which indeed has an impact 
on therapeutic patient management regarding surgical decision-
making versus neoadjuvant or palliative chemotherapy. The high 
NPV of PET/CT could be demonstrated by the fact that 60 surgi-
cally excised lymph nodes did not at all show FDG uptake in PET 
and proved to be histologically benign. In this context, the pro-
spective study by Liao et al. [21] has to be mentioned, which un-
derlines the role of preoperative SUVmax analysis in patients with 
oral-cavity squamous cell cancer as a predictor of 5-year disease-
free survival.
SUVmax is the most frequently applied semi-quantitative PET 
parameter for the assessment of lesion dignity, therapy response, 
and tumor recurrence in clinical routine [1, 6]. PET hardware fea-
tures, patient body weight, blood glucose levels, and potential 
movement during scanning are known factors that influence SUV-
max [17, 21]. For this reason there is currently no standardized 
SUVmax cut-off value available that allows clear delineation be-
Fig. 4. Immunomarker expression patterns of E-Cadherin (a), Cyclin D (b), 
and Bcl2 (c) in benign lymph nodes and lymph node metastases of OSCC. Be-
nign lymph nodes demonstrated insignificant expression of E-Cadherin and 
Cyclin D (1–25%) but significantly high levels of Bcl2 (51–100%). Lymph node 
metastases were characterized by a significantly high expression of E-Cadherin 
(51–100%), very moderate levels of Bcl2 (1–25%), and almost no evidence of 
Cyclin D.
Fig. 5. Kaplan-Meier tumor-specific survival curve. 5 out of 9 patients died of 
tumor recurrence after 10 (2 ×), 11, 12, and 27 months. In 4 cases, non-cancer-
related death occurred after 3, 7, 17, and 30 months. Data for tumor-specific 
survival after 35 months was available for 28 patients, including 4 patients with 
non-cancer-related death.
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tween benign and malignant lesions. Our cut-off value of SUVmax 
< 3/˰ 3 for benign/malignant lymph nodes was entirely based on 
experience with previous PET/CT studies in patients with HNSCC 
[17]. We also performed logistic regression analysis to confirm SU-
Vmax as a useful predictor for lymph node dignity analysis; the 
cut-off value SUVmax < 3/˰ 3 resulted in best trade-off between 
sensitivity and specificity (Mc Nemar p value = 0.0082, kappa 0.74, 
sensitivity 100.0%, specificity 70%, PPV 85%, NPV 100%).
The assessment of molecular marker profiles in lymph node 
metastases in HNSCC, responsible for the aggressiveness of tumor 
growth, angiogenesis and metastatic spread, might represent a 
novel approach to diagnostic accuracy [22, 23]. Detection of indi-
vidual biomarkers could help clinicians and head-and-neck sur-
geons to establish personalized medicine, distinguish therapy re-
sponders from non-responders and avoid unnecessary treatment-
related morbidity.
In this study, we analyzed molecular markers in 63 excised 
lymph nodes. The number of 63 lymph nodes is moderate, but it 
has to be mentioned that dedicated reading and reporting between 
the radiologist, the head-and-neck surgeon, and the pathologist al-
lowed for a precise level-to-level histological analysis of these sur-
gically resected lymph nodes, which is rarely found in the literature 
[11, 23]. Besides the evaluation of SUVmax, nodal size and histol-
ogy, the expression levels for VEGF, E-Cadherin, EGFR, Ki-67, Cy-
clin D1, Bcl2, HPV-16, and HPV-18 were assessed.
Unlike Baumann et al. [13], we could not prove significant 
nodal HPV-16 and -18 expression. It has to be mentioned that we 
only performed immunohistochemical analysis of lymphatic tissue 
and not of the primary tumor because that was not an integral part 
of our study. The fact that we had HPV-negative lymph nodes 
might be due to the fact that these OSCCs belong to the HPV 
DNA-negative group, the so-called tobacco-related HNSCCs, with 
poorer prognosis than the HPV-positive tumors [24, 25]. We did 
not find any correlation between the cellular proliferation marker 
Ki-67, SUVmax and lymph node histology. Ki-67 is a routinely 
used molecular marker with still unclear significance [25, 26].
Although VEGF is expressed in more than 80% of HNSCCs, 
this marker, responsible for tumor spread, metastatic potential, 
and treatment failure [6], was not evident in our nodal immu-
nostainings and could therefore not be correlated with SUVmax 
and lymph node histology. The absence of significant VEGF ex-
pression may be linked to the fact that, in our 33 cases of OSCC, 
only 5 patients were potential therapy non-responders who died 
from tumor recurrence. EGFR expression was one of the first mo-
lecular markers of angiogenesis being targeted as an anticancer 
agent in HNSCC. We had poor results for EGFR expression, which 
did not allow correlation with SUVmax and lymph node histology. 
As overexpression of this marker is usually associated with reduced 
overall survival and tumor recurrence, it can be assumed that the 
lymph nodes associated with OSCC in our patients were not repre-
sentative of aggressive tumor growth.
Out of the 3 molecular markers E-Cadherin, Cyclin D1, and 
Bcl2, we could unfortunately only prove statistically relevant re-
sults for E-Cadherin and Bcl2 (fig. 3a–c). We found a correlation 
between E-Cadherin expression and lymph node metastases in 
OSCC, which was confirmed by Mostaan et al. [27]. Downregula-
tion of this adhesion molecule is responsible for loss of tumor cell 
differentiation, increased invasiveness and metastatic potential 
[28]. Malignant lymph nodes showed significant expression of E-
Cadherin in our study, which might be responsible for well-differ-
entiated OSCCs with lower tendency towards lymph node 
metastasis.
We can confirm the uncertain role of Cyclin D1 as a molecular 
marker in OSCC, as also reported by Maahs et al. [29]. Patients 
showed no relevant expression in benign and malignant lymph 
nodes so that it is most unlikely that Cyclin D1 could serve as prog-
nostically valuable biomarker for therapy decisions in nodal metas-
tases of HNSCC.
Significantly high expression levels of Bcl2 were found in the 
benign lymph nodes. Bcl2 represents an immunomarker that is 
also present in physiological oral mucosa [29]. Lacking expression 
in lymph node metastases adds to the assumption that well-differ-
entiated OSCCs with less invasive potential and improved overall 
survival were diagnosed in our patients. At the same time, we dis-
covered high expression levels of E-Cadherin in lymph node me-
tastases, which have been made responsible for well-differentiated 
OSCC with less tendency of nodal spread.
In conclusion, in this study, we could confirm the tremendous 
contribution of 18F-FDG-PET/CT to lymph node staging in OSCC. 
There is a correlation between SUVmax, lymph node histology and 
nodal size, which allows lymph node status prediction. Although 
the awareness of lymph node molecular marker expression and its 
effect on therapeutic management is growing, understanding the 
molecular marker patterns associated with HNSCC and OSCC still 
remains a challenge, and studies have to continue in search of the 
appropriate marker that can be integrated into clinical practice.
At present, SUV level-based 18F-FDG-PET/CT and the associ-
ated high NPV of SUVmax in OSCC remains the most reliable di-
agnostic approach to lymph node staging and cannot be outper-
formed by nodal molecular marker expression profiles, which re-
quire further investigation.
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